Cargando…

Clinical Characteristics and Endovascular Treatment for Spinal Dural Arteriovenous Fistula in Japan: Japanese Registry of Neuroendovascular Therapy 2 and 3

A subgroup analysis of spinal vascular lesions registered in the Japanese Registry of Neuroendovascular Therapy 2 (JR-NET2) and JR-NET3 was performed. About 172 analyzable cases of spinal dural arteriovenous fistula (SDAVF) were assessed, including the characteristics, treatment strategy, and treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: TSURUTA, Wataro, MATSUMARU, Yuji, IIHARA, Koji, SATOW, Tetsu, SAKAI, Nobuyuki, KATSUMATA, Masahiro, HOSOO, Hisayuki, SATO, Masayuki, ITO, Yoshiro, MARUSHIMA, Aiki, HAYAKAWA, Mikito, ISHIKAWA, Eiichi, MATSUMURA, Akira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japan Neurosurgical Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923160/
https://www.ncbi.nlm.nih.gov/pubmed/31708513
http://dx.doi.org/10.2176/nmc.st.2018-0218
_version_ 1783481472382926848
author TSURUTA, Wataro
MATSUMARU, Yuji
IIHARA, Koji
SATOW, Tetsu
SAKAI, Nobuyuki
KATSUMATA, Masahiro
HOSOO, Hisayuki
SATO, Masayuki
ITO, Yoshiro
MARUSHIMA, Aiki
HAYAKAWA, Mikito
ISHIKAWA, Eiichi
MATSUMURA, Akira
author_facet TSURUTA, Wataro
MATSUMARU, Yuji
IIHARA, Koji
SATOW, Tetsu
SAKAI, Nobuyuki
KATSUMATA, Masahiro
HOSOO, Hisayuki
SATO, Masayuki
ITO, Yoshiro
MARUSHIMA, Aiki
HAYAKAWA, Mikito
ISHIKAWA, Eiichi
MATSUMURA, Akira
author_sort TSURUTA, Wataro
collection PubMed
description A subgroup analysis of spinal vascular lesions registered in the Japanese Registry of Neuroendovascular Therapy 2 (JR-NET2) and JR-NET3 was performed. About 172 analyzable cases of spinal dural arteriovenous fistula (SDAVF) were assessed, including the characteristics, treatment strategy, and treatment outcome. SDAVF was more common in middle-aged and older males. The most commonly affected area was the thoracolumbosacral region (83.7%), and most cases had a non-hemorrhagic onset (89.0%). Complete obliteration was achieved in 54.7%. Treatment-related complications occurred in three patients (7.0%). Post-treatment neurological improvement was achieved in 48.3%. The primary endpoint [modified Rankin Scale (mRS) score of 0–2 on postoperative day 30] was achieved in 60.5% of the cases. As a new discovery, the incidence of cervical SDAVF increased from 1.8% in JR-NET2 to 19.7% in JR-NET3. Compared with non-cervical SDAVF, cervical SDAVF was characterized by a higher proportion of hemorrhagic onset (P <0.01), incomplete obliteration of the shunt (P <0.01), and embolization-related complications (P = 0.01). Overall, a mRS of 0–2 on postoperative day 30 was correlated with a pre-treatment mRS of 0–2 (P <0.01) in a univariate analysis. Complete obliteration of the shunt was the only predictor of postoperative neurological improvement (P = 0.001) in a multivariate analysis. Endovascular treatment for SDAVF has been safely administered in Japan. The incidence of cervical SDAVF, which has more aggressive features, appears to be increasing. Early diagnosis and complete obliteration of the shunt are important for improving the treatment outcomes of patients with SDAVF.
format Online
Article
Text
id pubmed-6923160
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Japan Neurosurgical Society
record_format MEDLINE/PubMed
spelling pubmed-69231602019-12-23 Clinical Characteristics and Endovascular Treatment for Spinal Dural Arteriovenous Fistula in Japan: Japanese Registry of Neuroendovascular Therapy 2 and 3 TSURUTA, Wataro MATSUMARU, Yuji IIHARA, Koji SATOW, Tetsu SAKAI, Nobuyuki KATSUMATA, Masahiro HOSOO, Hisayuki SATO, Masayuki ITO, Yoshiro MARUSHIMA, Aiki HAYAKAWA, Mikito ISHIKAWA, Eiichi MATSUMURA, Akira Neurol Med Chir (Tokyo) Special Topic A subgroup analysis of spinal vascular lesions registered in the Japanese Registry of Neuroendovascular Therapy 2 (JR-NET2) and JR-NET3 was performed. About 172 analyzable cases of spinal dural arteriovenous fistula (SDAVF) were assessed, including the characteristics, treatment strategy, and treatment outcome. SDAVF was more common in middle-aged and older males. The most commonly affected area was the thoracolumbosacral region (83.7%), and most cases had a non-hemorrhagic onset (89.0%). Complete obliteration was achieved in 54.7%. Treatment-related complications occurred in three patients (7.0%). Post-treatment neurological improvement was achieved in 48.3%. The primary endpoint [modified Rankin Scale (mRS) score of 0–2 on postoperative day 30] was achieved in 60.5% of the cases. As a new discovery, the incidence of cervical SDAVF increased from 1.8% in JR-NET2 to 19.7% in JR-NET3. Compared with non-cervical SDAVF, cervical SDAVF was characterized by a higher proportion of hemorrhagic onset (P <0.01), incomplete obliteration of the shunt (P <0.01), and embolization-related complications (P = 0.01). Overall, a mRS of 0–2 on postoperative day 30 was correlated with a pre-treatment mRS of 0–2 (P <0.01) in a univariate analysis. Complete obliteration of the shunt was the only predictor of postoperative neurological improvement (P = 0.001) in a multivariate analysis. Endovascular treatment for SDAVF has been safely administered in Japan. The incidence of cervical SDAVF, which has more aggressive features, appears to be increasing. Early diagnosis and complete obliteration of the shunt are important for improving the treatment outcomes of patients with SDAVF. The Japan Neurosurgical Society 2019-12 2019-11-09 /pmc/articles/PMC6923160/ /pubmed/31708513 http://dx.doi.org/10.2176/nmc.st.2018-0218 Text en © 2019 The Japan Neurosurgical Society This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Special Topic
TSURUTA, Wataro
MATSUMARU, Yuji
IIHARA, Koji
SATOW, Tetsu
SAKAI, Nobuyuki
KATSUMATA, Masahiro
HOSOO, Hisayuki
SATO, Masayuki
ITO, Yoshiro
MARUSHIMA, Aiki
HAYAKAWA, Mikito
ISHIKAWA, Eiichi
MATSUMURA, Akira
Clinical Characteristics and Endovascular Treatment for Spinal Dural Arteriovenous Fistula in Japan: Japanese Registry of Neuroendovascular Therapy 2 and 3
title Clinical Characteristics and Endovascular Treatment for Spinal Dural Arteriovenous Fistula in Japan: Japanese Registry of Neuroendovascular Therapy 2 and 3
title_full Clinical Characteristics and Endovascular Treatment for Spinal Dural Arteriovenous Fistula in Japan: Japanese Registry of Neuroendovascular Therapy 2 and 3
title_fullStr Clinical Characteristics and Endovascular Treatment for Spinal Dural Arteriovenous Fistula in Japan: Japanese Registry of Neuroendovascular Therapy 2 and 3
title_full_unstemmed Clinical Characteristics and Endovascular Treatment for Spinal Dural Arteriovenous Fistula in Japan: Japanese Registry of Neuroendovascular Therapy 2 and 3
title_short Clinical Characteristics and Endovascular Treatment for Spinal Dural Arteriovenous Fistula in Japan: Japanese Registry of Neuroendovascular Therapy 2 and 3
title_sort clinical characteristics and endovascular treatment for spinal dural arteriovenous fistula in japan: japanese registry of neuroendovascular therapy 2 and 3
topic Special Topic
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923160/
https://www.ncbi.nlm.nih.gov/pubmed/31708513
http://dx.doi.org/10.2176/nmc.st.2018-0218
work_keys_str_mv AT tsurutawataro clinicalcharacteristicsandendovasculartreatmentforspinalduralarteriovenousfistulainjapanjapaneseregistryofneuroendovasculartherapy2and3
AT matsumaruyuji clinicalcharacteristicsandendovasculartreatmentforspinalduralarteriovenousfistulainjapanjapaneseregistryofneuroendovasculartherapy2and3
AT iiharakoji clinicalcharacteristicsandendovasculartreatmentforspinalduralarteriovenousfistulainjapanjapaneseregistryofneuroendovasculartherapy2and3
AT satowtetsu clinicalcharacteristicsandendovasculartreatmentforspinalduralarteriovenousfistulainjapanjapaneseregistryofneuroendovasculartherapy2and3
AT sakainobuyuki clinicalcharacteristicsandendovasculartreatmentforspinalduralarteriovenousfistulainjapanjapaneseregistryofneuroendovasculartherapy2and3
AT katsumatamasahiro clinicalcharacteristicsandendovasculartreatmentforspinalduralarteriovenousfistulainjapanjapaneseregistryofneuroendovasculartherapy2and3
AT hosoohisayuki clinicalcharacteristicsandendovasculartreatmentforspinalduralarteriovenousfistulainjapanjapaneseregistryofneuroendovasculartherapy2and3
AT satomasayuki clinicalcharacteristicsandendovasculartreatmentforspinalduralarteriovenousfistulainjapanjapaneseregistryofneuroendovasculartherapy2and3
AT itoyoshiro clinicalcharacteristicsandendovasculartreatmentforspinalduralarteriovenousfistulainjapanjapaneseregistryofneuroendovasculartherapy2and3
AT marushimaaiki clinicalcharacteristicsandendovasculartreatmentforspinalduralarteriovenousfistulainjapanjapaneseregistryofneuroendovasculartherapy2and3
AT hayakawamikito clinicalcharacteristicsandendovasculartreatmentforspinalduralarteriovenousfistulainjapanjapaneseregistryofneuroendovasculartherapy2and3
AT ishikawaeiichi clinicalcharacteristicsandendovasculartreatmentforspinalduralarteriovenousfistulainjapanjapaneseregistryofneuroendovasculartherapy2and3
AT matsumuraakira clinicalcharacteristicsandendovasculartreatmentforspinalduralarteriovenousfistulainjapanjapaneseregistryofneuroendovasculartherapy2and3